2020
Coagulation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke
Rohmann J, Huo S, Sperber P, Piper S, Rosendaal F, Heuschmann P, Endres M, Liman T, Siegerink B. Coagulation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke. Journal Of Thrombosis And Haemostasis 2020, 18: 3316-3324. PMID: 32935900, DOI: 10.1111/jth.15092.Peer-Reviewed Original ResearchConceptsFirst ischemic strokeIschemic strokeCoagulation factor XIIVascular outcomesHazard ratioRisk factorsActivity levelsFactor XIICox proportional hazards modelIschemic stroke eventsRecurrent vascular eventsWorse vascular outcomesCardiovascular risk factorsIschemic stroke patientsFirst thrombotic eventSecondary eventsProportional hazards modelModerate ischemic stroke patientsFactor activity levelsRecurrent strokeCause mortalityProspective cohortVascular eventsThrombotic eventsStroke events
2019
Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B)
Sperber P, Siegerink B, Huo S, Rohmann J, Piper S, Prüss H, Heuschmann P, Endres M, Liman T. Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B). Stroke 2019, 50: 3213-3219. PMID: 31526121, DOI: 10.1161/strokeaha.119.026100.Peer-Reviewed Original ResearchConceptsSecondary vascular eventsFunctional outcomeVascular eventsHigh titersNMDAR1-ABSeronegative patientsSeropositive patientsFirst strokeLong-term clinical outcomesLong-term functional outcomeCombined end pointRecurrent vascular eventsOutcomes of patientsPoor functional outcomeSub-group analysisOutcomes of interestAnti-NMDAAutoimmune encephalitisCardiovascular riskProspective cohortRankin ScaleHazard ratioClinical outcomesNeuroprotective effectsReceptor antibodies